Abstract:Background: Previously, long non-coding RNA (lncRNA) gene AP001469.3 was reported to participate in the construction of an immune-related lncRNA signature, which showed promising clinical predictive value in colorectal cancer (CRC) patients. However, the clinical and immunological significance and biological function of AP001469.3 in CRC remain unclear. In this study, we aim to explore the roles of AP001469.3 in CRC progression, thereby opening an avenue for CRC treatment. Methods: Our study collected data from The Cancer Genome Atlas (TCGA) database and investigated the role of AP001469.3 in CRC through bioinformatics analysis. Cell-type Identification By Estimating Relative Subsets Of known RNA Transcripts (CIBERSORT) and Estimation of STromal and Immune cells in MAlignant Tumor tissues using Expression data (ESTIMATE) methods evaluated the immune infiltration. The biological functions of AP001469.3 in CRC were validated by in vitro experiments. Gene set enrichment analysis (GSEA) was used to estimate the enrichment of functional pathways and gene signatures. Results: In this work, high expression of AP001469.3 was found in CRC and was positively associated with tumor-node-metastasis (TNM) stage in CRC. AP001469.3 expression had a strong relationship with microsatellite instability (MSI) in colon adenocarcinoma (COAD). Additionally, AP001469.3 expression was associated with StromalScore, ImmuneScore, ESTIMATEScore, immune cell infiltration (ICI) levels and immune checkpoint (ICP) genes expression in CRC. Subsequent results showed that immunotherapy could be more effective in CRC patients with low-AP001469.3 expression using the immunophenoscore (IPS). We confirmed that the transcript of AP001469.3 gene ENST00000430259 was highly expressed in CRC tissues and cell lines. In vitro experiments indicated that ENST00000430259 knockdown reduced the proliferation, migration and invasion of CRC cells. Finally, our GSEA results showed that the majority of the differentially enriched signaling pathways between the high- and low-AP001469.3 expression groups were immune-related. Conclusions: Taken together, our study demonstrates that lncRNA gene AP001469.3 is associated with immunological characteristics in CRC and promotes malignant progression of CRC. Moreover, AP001469.3 can be potentially used as an immunotherapeutic indicator and a therapeutic target for CRC patients.

Genome-wide Study of ER-regulated Lncrnas Shows AP000439.3 May Function As a Key Regulator of Cell Cycle in Breast Cancer.

Epigenomics-based Identification of Oestrogen-Regulated Long Noncoding RNAs in ER+ Breast Cancer.

Lnc-DC Promotes Estrogen Independent Growth and Tamoxifen Resistance in Breast Cancer

Long Non‑coding RNA Profile Revealed by Microarray Indicates That Lnccuedc1 Serves a Negative Regulatory Role in Breast Cancer Stem Cells.

ERα upregulates the expression of long non-coding RNA LINC00472 which suppresses the phosphorylation of NF-κB in breast cancer

Genome-Wide Investigation of Genes Regulated by ERα in Breast Cancer Cells.

Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression

LINC00472 expression is regulated by promoter methylation and associated with disease-free survival in patients with grade 2 breast cancer

Supplementary Data from Analysis of the Estrogen Receptor-Associated LncRNA Landscape Identifies a Role for ERLC1 in Breast Cancer Progression

Identification and Functional Annotation of Genome-Wide ER-Regulated Genes in Breast Cancer Based on ChIP-Seq Data.

Supplementary Data from ERINA is an Estrogen-Responsive LncRNA That Drives Breast Cancer Through the E2F1/RB1 Pathway

The roles of lncRNA AP001469.3 in clinical implications, immune landscape and carcinogenesis of colorectal cancer

Transcriptional Activation Of Nlp By Estrogen-Er Alpha In Breast Cancer

Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics.

c-Jun/AP-1 overexpression reprograms ERα signaling related to tamoxifen response in ERα-positive breast cancer

Expression and clinical significance of estrogen-regulated long non-coding RNAs in estrogen receptor α-positive ovarian cancer progression.

Novel breast specific long non-coding RNA LINC00993 acts as a tumor suppressor in Triple negative breast cancer

LINC00473 Mediates Cyclin D1 Expression Through a Balance Between Activation and Repression Signals in Breast Cancer Cells.

Apolipoprotein L3 Inhibits Breast Cancer Proliferation and Modulates Cell Cycle Via the P53 Pathway

The Long Non-coding RNA LINC01705 Regulates the Development of Breast Cancer by Sponging miR-186-5p to Mediate TPR Expression as a Competitive Endogenous RNA

Identification of Key lncRNA–mRNA Pairs and Functional lncRNAs in Breast Cancer by Integrative Analysis of TCGA Data